NasdaqCM:VRDNBiotechs
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval
Viridian Therapeutics (VRDN) is in focus after the FDA approved Lumvoa for thyroid eye disease, covering both active and chronic forms. This marks the company’s first commercial product and a new chapter for the stock.
See our latest analysis for Viridian Therapeutics.
The FDA approval has put Viridian Therapeutics back on traders’ radar, with a 30 day share price return of 23.85% and a 90 day share price return of 35.12%. However, the year to date share price return is still down 34.16%,...